Languages
简体中文
繁體中文
English
日本語
한국어
Bahasa Indonesia
Tiếng Việt
Sign In
Send a Release
Products
News
Resources
Contact
Search
Search
Products
News
Resources
Contact
Overview
Content Creation
Distribution
Monitoring & Insights
Influencer Database
Falcon
All Products
Send a Release
News
Products
Resources
Contact
Overview
Latest
Regional
Mainland China
Japan
Korea
Indonesia
Malaysia
Singapore
Thailand
Vietnam
Australia
Industry
Auto & Transportation
Business Technology
Consumer Products & Retail
Consumer Technology
Energy
Entertainment & Media
Environment
Financial Services
General Business
Health
Heavy Industry & Manufacturing
Policy & Public Interest
Sports
Telecommunications
Travel
Food and Beverages
Advertising, Marketing and Media
Exhibition
Real Estate and Furniture
Trending Topics
Personnel Announcements
Earnings
New Technologies & New Products
Investment & Financing
Carbon Neutral
China International Consumer Products Expo
Olympics
Summer Event
Environmental, Social, Governance (ESG)
Sustainability
Embedded World
Black Friday & Cyber Monday
Belt & Road
Artificial Intelligence
IFA 2024
Holiday Season
Consumer Electronics Show (CES)
Canton Fair
Earth Day
Blockchain
Mother's Day
China International Import Expo
5G
Multimedia
Other Languages
Malaysian
Thai
Public Company News
Send a Release
Resources
Products
News
Contact
Overview
Beyond PR Blog
Media Coffee
Client Stories
White Papers
Events in APAC
Media Room
Send a Release
Contact
Products
Resources
News
Asia Pacific Offices
Request More Information
Alert / Newsletter Subscription
Our Presence on Social Media Sites
FAQs
Send a Release
Products
News
Resources
Contact
Send a Release
成都威斯克生物医药有限公司
Media Room
Latest News
Photo News
Photo News
Time
All
2023
2022
2021
China Approves the World's First Vaccine against XBB Descendent Lineages of SARS-CoV-2 for Emergency Use
2023-06-09 11:59
3345
Report
The First of Its Kind in the World: The Recombinant Multivalent COVID-19 Protein Vaccine against XBB Variants by WestVac Biopharma/West China Medical Center, Sichuan University has been Approved for Clinical Trials by The National Medical Products Administration of China.
2023-05-18 21:23
4496
Report
Significant Progress Made on the Trivalent Recombinant Protein COVID-19 Vaccine against Subvariants including XBB.1.5 and BA.5 by WestVac Biopharma
2023-02-20 12:43
3444
Report
COVID-19 Vaccine Developed by WestVac BioPharma Has High Titer Neutralizing Antibodies Against Omicron
2021-12-24 19:57
6960
Report
Share:
Share to wechat: